First, we analysed the expression of surface markers (CD27, CD38, CD49d and HLA-DR) on CLL cells in patients treated with ibrutinib, idelalisib, and venetoclax and we revealed no difference in the analysed markers between these patient groups. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.